importantli
sofosbuvir
safe
well
toler
mg
daili
week
therapeut
regimen
sofosbuvir
activ
metabolit
howev
show
extrem
high
intracellular
stabil
hypothes
infect
could
also
suscept
sofosbuvir
convinc
design
run
clinic
trial
evalu
effect
sofosbuvir
mg
combin
velpatasvir
mg
addon
treatment
addit
standard
care
howev
believ
manuscriptcorrespond
made
avail
intern
scientif
commun
soon
possibl
help
esteem
journal
sever
acut
respiratori
syndrom
coronaviru
relat
diseas
terribl
spread
countri
area
territori
till
april
nd
valu
confirm
case
total
death
http
human
pathogen
coronavirus
sarscov
bind
target
cell
angiotensinconvert
enzym
express
epitheli
cell
lung
intestin
kidney
blood
vessel
abil
enter
infect
human
nervou
system
base
strong
express
target
throughout
brain
also
consid
howev
despit
decad
extens
research
specificeffect
therapi
approv
ritonavir
actual
role
treatment
still
unclear
preclin
data
suggest
potenti
benefit
howev
recent
data
fail
confirm
kaletra
efficaci
treatment
http
outbreak
continu
spread
around
world
absenc
clinic
proven
antivir
therapi
seriou
challeng
treatment
sever
case
accord
figur
tenofovir
alafenamid
alovudin
azt
incorpor
rnadepend
rna
polymeras
rdrp
enzym
sarscov
well
perman
block
incorpor
polymeras
extens
termin
consid
compound
permanentstrong
termin
rdrp
due
wide
avail
fda
approv
drug
sofosbuvir
tenofovir
azt
express
hope
drug
would
evalu
quickli
laboratori
clinic
trial
treatment
research
chien
et
al
could
offer
one
best
rdrp
inhibitor
introduc
scientif
commun
sofosbuvir
clinic
approv
drug
potent
antivir
effect
hepat
c
viru
hcv
divers
genotyp
acid
dissoci
constant
pka
sofosbuvir
around
class
compound
possess
highsolubl
lowperm
phosphoryl
sofosbuvir
within
host
cell
hepatocyt
convert
activ
nucleosid
triphosph
termin
rna
replic
nascent
viral
genom
competit
nucleotid
viru
sofosbuvir
exhibit
potent
antivir
activ
even
liver
cirrhosi
well
prior
null
respons
ribavirin
ifn
moreov
sofosbuvir
fast
respons
estim
mean
exert
potenc
sofosbuvir
offer
high
heal
rate
low
side
effect
signific
efficaci
short
administr
period
good
toler
potent
resist
defens
eg
fission
positron
fusion
report
patient
receiv
combin
sofosbuvir
ribavirin
without
express
primari
sofosbuvir
resist
mutat
moreov
sofosbuvir
exert
pangenotyp
antivir
effect
hcv
genotyp
antivir
drug
interfer
major
drug
metabol
enzym
cytochrom
arch
med
re
system
therefor
low
drugdrug
interact
includ
antiretrovir
opioid
substitut
therapi
calcineurin
inhibitor
benefici
treatment
tradit
difficult
treat
sofosbuvir
rapid
clinic
develop
due
high
efficaci
safeti
profil
moreov
sofosbuvir
prescrib
oral
singl
daili
dose
due
promis
pharmacokinet
profil
bioavail
sofosbuvir
high
maximum
plasma
concentr
c
max
h
oral
administr
interest
sofosbuvir
clinic
approv
antihepat
c
viru
hcv
drug
abil
suppress
differ
famili
virus
differ
research
group
demonstr
safe
drug
inhibit
replic
flavivirus
includ
zikv
denv
yellow
fever
viru
yfv
moreov
ferreira
ac
et
al
observ
beyond
member
flavivirida
famili
sofosbuvir
also
inhibit
chikungunya
viru
replic
found
sofosbuvir
three
time
select
inhibit
chikungunya
viru
chikv
product
also
less
cytotox
human
hepatoma
cell
ribavirin
chikv
member
togavirida
famili
positivesens
singlestrand
rna
genom
rdrp
enzym
code
gene
rna
polymeras
positivesens
rna
virus
wellconserv
motif
regard
sinc
coronavirus
famili
envelop
positivestrand
rna
virus
conserv
polymeras
rdrp
like
effect
inhibit
sofosbuvir
hypothes
infect
could
also
suscept
drug
prior
discoveri
sofosbuvir
varieti
nucleosid
analog
examin
antihepat
c
hcv
treatment
exhibit
rel
low
potenc
owe
substrat
specif
kinas
activ
nucleosid
analogu
often
proce
insuffici
design
sofosbuvir
avoid
slow
step
build
first
phosphat
group
structur
drug
synthesi
moreov
addit
group
attach
phosphat
temporarili
arch
med
re
mask
neg
charg
phosphat
group
therebi
facilit
entri
prodrug
infect
cell
although
hepat
cell
effect
system
remov
sofosbuvir
phosphat
protect
function
assay
reveal
cell
relev
infect
also
activ
sofosbuvir
one
principl
cell
type
product
infect
chikv
epitheli
cell
varieti
nonhuman
human
epitheli
cell
line
mention
sofosbuvir
metabol
activ
drug
capabl
effici
control
type
viru
insid
epitheli
cell
furthermor
sofosbuvir
appear
highli
activ
zikv
human
neuroepitheli
stem
cell
suppress
differ
infect
cell
line
could
explain
differ
intracellular
process
prodrug
lead
differ
concentr
activ
triphosph
metabolit
extent
drug
uptak
cytosol
level
metabol
enzym
ndk
involv
metabol
activ
sofosbuvir
infect
cell
two
main
determin
import
enzym
carboxylesteras
need
activ
sofosbuvir
hepat
cell
strongli
express
lower
level
enzym
express
howev
document
lung
cell
though
sofosbuvir
develop
treatment
hepatotrop
viru
design
facilit
intracellular
penetr
liver
tissu
statement
part
explain
success
uptak
intracellular
activ
sofosbuvir
alveolar
epitheli
cell
viral
reservoir
may
also
assum
cellular
uptak
prodrug
sofosbuvir
well
intracellular
concentr
biolog
activ
triphosph
metabolit
within
lung
epitheli
cell
low
though
local
lung
inflamm
may
enhanc
endotheli
permeabl
improv
epitheli
uptak
drug
diseas
state
featur
sofosbuvir
may
give
hope
may
intracellular
stabil
triphosph
metabolit
surpris
differ
stabil
nucleosid
analogu
triphosph
nucleotid
analogu
report
shown
triphosph
sofosbuvir
show
extrem
high
intracellular
stabil
h
also
made
respons
signific
persist
antihcv
effect
activ
drug
inhibit
babusi
et
al
also
confirm
observ
evalu
vitro
metabol
sofosbuvir
ribavirin
primari
human
hepatocyt
show
activ
effici
two
investig
drug
triphosph
metabolit
sofosbuvir
overal
although
sofosbuvir
current
list
potenti
option
drug
therapi
till
http
evid
advantag
action
drug
viral
rdrp
vitro
stabil
triphosph
drug
metabolit
least
interact
standard
care
constitut
rational
perform
trial
patient
infect
moreov
sofosbuvir
safe
well
toler
mg
daili
week
therapeut
regimen
clinic
relev
drugdrug
interact
rare
import
drug
interact
amiodaron
caus
bradycardia
sovaldi
sofosbuvir
prescrib
inform
foster
citi
ca
gilead
scienc
sofosbuvir
present
unusu
clean
safeti
profil
nucleotid
therapeut
safeti
profil
sofosbuvir
either
combin
pegifn
rbv
combin
ribavirin
alon
allor
regimen
excel
even
cirrhot
patient
also
vitro
sofosbuvir
exhibit
cytotox
mitochondri
toxic
bone
marrow
toxic
dose
multipl
effect
dose
convinc
design
run
clinic
trial
evalu
effect
sofosbuvir
mg
combin
velpatasvir
mg
addon
treatment
addit
standard
care
written
research
propos
submit
univers
research
councileth
committe
approv
propos
regist
iranian
registri
clinic
trial
code
http
clinic
trial
current
process
agreement
advoc
gener
sofosbuvir
beyond
treatment
hcvinfect
patient
repres
safe
arch
med
re
effect
antivir
option
compar
similar
antivir
agent
encourag
clinic
investig
consid
dualcompon
hcv
drug
velpatasvirsofosbuvir
repurpos
treatment
infect
howev
believ
manuscriptcorrespond
made
avail
intern
commun
soon
possibl
help
esteem
journal
